Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin vs Octreotide in Hepatorenal Syndrome
NCT07460908Completed
- Sponsor
- Lahore General Hospital
- Start
- May 2025
- Primary completion
- Oct 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of terlipressin in hepatorenal syndrome (HRS) (2 arms), sponsored by Lahore General Hospital. Primary endpoint: Treatment response based on serum creatinine at 48 hours. Started May 2025; status: completed.
02
Drugs
terlipressin
03
Conditions
hepatorenal syndrome (HRS)
Beyond the preview
Go deeper on NCT07460908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07460908.